Trial Profile
Amrubicin monotherapy for patients with platinum-refractory gastroenteropancreatic neuroendocrine carcinoma
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 11 Aug 2015
Price :
$35
*
At a glance
- Drugs Amrubicin (Primary)
- Indications Neuroendocrine carcinoma
- Focus Therapeutic Use
- 11 Aug 2015 New trial record